natgillin/translations-raw huggingface dataset:
is selected from is selected from phenyl, substituted phenyl, benzyl, substituted benzyl, biphenyl, substituted biphenyl, biphenylmethylene, substituted biphenylmethylene, naphthyl, substituted naphthyl, naphthylmethylene, and substituted naphthylmethylene. 
je odabran od je odabran od fenila, supstituiranog fenila, benzila, supstituiranog benzila, bifenila, supstituiranog bifenila, bifenilmetilena, supstituiranog bifenilmetilena, naftila, supstituiranog naftila, naftilmetilena, i supstituiranog naftilmetilena.
For their preparation, for example, solutions or dispersions of the compounds of the Formula (I) in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives, for example benzyl alcohol or other suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others, and, if appropriate, customary propellants, for example include carbon dioxide, CFC's, such as, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane; and the like. 
Za njihovu pripremu, na primjer, mogu se upotrijebiti otopine ili disperzije spojeva Formule (ID) u vodi, smjesi voda/alkohol ili prikladnoj otopini soli uporabom uobičajenih dodataka, na primjer, benzil alkohola ili ostalih prikladnih konzervansa, sredstava za poboljšanje apsorpcije za povećanje bioraspoloživosti, solubilizatora i slično, te ukoliko je to potrebno, propelenata koji uključuju, na primjer ugljikov dioksid, CFS poput diklorodifluorometana, triklorofluorometana ili diklorotetrafluoretana, te slično.
The duration of each trial is also important as a preference for the novel object only lasts during the first 1 or 2 minutes, after which time preference diminishes as both objects become familiar and are explored equally. 
Vrijeme trajanja pokusa je također važno jer pogodnost za novi predmet traje svega tijekom prvih 1 do 2 minute, nakon čega se prednost smanjuje jer oba predmeta postaju poznata 1 istražuju se jednako.
The ski boot of claim 17, said cuff is adjustable in height by way of a small tongue adapted to be selectively made to protrude from a rear area of the upper perimetral edge of said cuff. 
Cipela za skijanje prema jednom ili više prethodnih zahtjeva, naznačena time, da se manžeti (6) može podesiti visina zbog prisutnosti malog jezička (35), koji je prilagođen selektivnoj izradi, tako da strši od stražnjeg područja gornjeg obodnog ruba (58) same manžete (6).
The composition for use of claim 5 or 6 comprising at least one of the following drug combinations: Torasemide and levodopa, or salts, prodrugs, derivatives of any chemical purity, or sustained release formulations thereof, 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 5 ili 6, naznačen time što sadrži najmanje jednu od sljedećih kombinacija lijekova, ili njihovih soli, ili njihovih formulacija s produljenim otpuštanjem:
The process for preparing a vaccine composition as claimed in claim 17, wherein the conjugate obtained in a) is combined with diphtheria toxoid, tetanus toxoid, and acellular Bordetella pertussis antigens toxoid, pertactin, agglutinogens and filamentous hemagglutinin. 
Postupak za pripravu pripravka cjepiva prema zahtjevu 12 ili 13, naznačen time da se konjugat dobiven u koraku b) kombinira s toksoidom difterije, toksoidom tetanusa, 1 5 acelularnih antigena Bordetella pertussis, koji su toksoid, pertaktin, aglutinogeni 1 filamentozni hemaglutinin.
As can be seen in Figures 6 and 7, upon oral administration of rapamycin a rapid rise in rapamycin concentration in the blood was observed with a maximum concentration reached at approximately 30 minutes. 
Kako se vidi na slikama 6 i 7, nakon oralne primjene rapamicina opažen je brzi porast koncentracije rapamicina u krvi, pri čemu se maksimalna koncentracija doseže nakon približno 30 minuta.
The vaccine of any one of embodiments 20 to 28, which is a trivalent influenza vaccine. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da cjepivo jest monovalentno cjepivo protiv pandemijske gripe.
Floor panel (24, 37, 41, 52, 70, 88, 97, 106, 114) as claimed in any of the foregoing claims, wherein the second locking element (32, 49, 56, 74, 92) is positioned at a distance from an upper side (48a) of the downward groove (30, 48). 
Podni panel (24, 37, 41, 52, 70, 88, 97, 106, 114) prema bilo kojem od prethodnih zahtjeva, gdje je drugi element zaključavanja (32, 49, 56, 74, 92) smješten na udaljenosti od gornje strane (48a) dolje okrenutog jezičca (30, 48).
Glycogen phosphorylase exists in two interconvertible forms: the dephosphorylated inactive form (phosphorylase b) and the phosphorylated active form (phosphorylase a) (reviewed by Newgard et al. (1989) Crit. 
Glikiogen fosforilaza postoji u dva međusobno izmjenjiva oblika: defosforiliranom neaktivnom obliku (fosforilaza b) i fosforiliranom aktivnom obliku (fosforilaza a) (izdanje revijalnog rada Newgard i suradnici (1989) Crit.
vi a bradykinin 1 receptor or an angiotensin II antagonist, vii a cyclooxygenase inhibitor, a bisphosphonate, a histone deacetylase inhibitor, a heparanase inhibitor (prevents heparan sulphate degradation), preferably PI-88, a biological response modifier, preferably a lymphokine or interferons,, an ubiquitination inhibitor, or an inhibitor which blocks anti-apoptotic pathways, 
receptor bradikinina 1 ili antagonist angiotenzina II; vii. inhibitor ciklooksigenaze, inhibitor bisfosfonata, inhibitor histonske deacetilaze, inhibitor heparanaze (sprečava degradaciju heparan-sulfata), poželjno PI-88, modifikator biološkog odgovora, poželjno limfokin ili interferoni, inhibitor ubikvitinacije, ili inhibitor koji blokira antiapoptotske puteve; viii. inhibitor onkogenih Ras-izoforma, poželjno H-Ras, K-Ras ili N-Ras, ili inhibitor famezil-transferaze, poželjno L-744, 832 ili DK8G557; ix.
The whole was then heated up to 94°C and it was then additioned with the acid catalyst (formic acid); the pH was equal to 4.5. The mixture was then condensed at 95°C until reaching a viscosity of 100 mPas (measured at 20°C). 
Zagrijemo do 94"C te dodamo kiseli katalizator (mravlju kiselinu), pH je 4,5. Kondenziramo kod 95*C do viskoznosti 0,1 Pa.s. (mjereno kod 20%C).
The method of claim 14, wherein said Ig motif 1 comprises amino acid residues 30-129 of SEQ ID NO: 3, and said Ig motif 2 comprises amino acid residues 135-221 of SEQ ID NO: 3. 
Farmaceutski pripravak u skladu s patentnim zahtjevima 1 do 3, naznačen time što domena koja se veže na Ig2 SLIT sadrži aminokiselinske ostatke 151-237 iz SEQ ID NO: 1 ili aminokiselinski ostaci 135-221 iz SEQ ID NO:3.
A platform (1) according to claim 3, wherein at least the bottom plane (2) comprises a layer (25) made of alveolar polymer. 
Platforma (1) u skladu sa patentnim zahtjevom 3 ili patentnim zahtjevom 4, gdje najmanje donja ravnina (2) sadrži sloj (25) koji je napravljen od alveolarnog polimera.
Locomotor activity was recorded in the reference group (haloperidol) at 1 hour after administration. 
Lokomotorno djelovanje je snimano u referentnoj skupini (haloperidol) jedan sat nakon primjene.
A product comprising follicle stimulating hormone (FSH) for use in the treatment of infertility in a patient having serum AMH level of <15 pmol/L, wherein the product is to be administered at a dose of, or equivalent to, 11 to 13 µg human derived recombinant FSH per day, the recombinant FSH including a2, 3- and a2, 6- sialylation wherein 1 % to 50% of the total sialylation is a2, 6- sialyation, and 50% to 99% of the total sialylation is a 2,3- sialyation; and wherein the treatment of infertility comprises a step of determining the serum AMH level of the patient, and a step of administering the dose to a patient having serum AMH level of <15 pmol/L. 
HR P20160145 T1 PATENTNI ZAHTJEVI Proizvod, koji sadrži folikulostimulirajući hormon (FSH) za uporabu kod liječenja neplodnosti kod pacijenta, koji ima razinu AMH u serumu <15 pmol/L., naznačen time da se proizvod mora administrirati u dozi ili u ekvivalentu doze od 11 ug do 13 ug ljudskog dobivenog rekombinantnog FSH dnevno, pri čemu rekombinantni FSH sadrži 02,3- i 02,6-sijaliniziranje, pri čemu je od 1% do 50% ukupnog sijaliniziranja 02,6-sijaliniziranje i od 50% do 99% ukupnog sijaliniziranja je 02,3-sijaliniziranje; te pri čemu liječenje neplodnosti sadrži korak određivanja razine AMH u serumu kod pacijenta i korak administracije doze pacijentu, koji ima razinu AMH u serumu <15 pmol/L.
optionally, determining at least one of the ratios of concentrations selected from the group consisting of SEQ ID NO: 10/SEQ ID NO: 4, and SEQ ID NO: 7/SEQ ID NO: 4, wherein SEQ ID NO: 4 concentration is determined by quantitative PCR in said human feces sample using primers with at least 90% identity with respect to SEQ ID NO: 5-6; and 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se razine SEQ ID NO: 1 određuje upotrebom početnica sa slijedom SEQ ID NO: 2 1 13, razine SEQ ID NO: 4 se određuje upotrebom početnica sa slijedom SEQ ID NO: 5 1 6; razine SEQ ID NO: 7 se određuje upotrebom početnica sa slijedom SEQ ID NO: 819; i razine SEQ ID NO: 10 se određuje upotrebom početnica sa slijedom SEQ ID NO: 11112.
A is an organic cation; 
A je organski kation;
A process for preparing a compound of formula (II), according to claim 7 wherein (R1)p is 2-fluoro-4-(trifluoromethyl)phenyl, the process comprising the following steps: wherein: 
Postupak dobivanja spoja formule (II), u skladu s patentnim zahtjevom 7, gdje (Ri), je 2-fluor-4-(trifluormetil)fenil, naznačen time što se navedeni postupak sastoji u sljedećim koracima:
A preferred plasticizer for use with the enteric coating polymer is a combination of triethyl citrate and glycerol monostearate. Preferred fillers include, but are not limited to, microcrystalline cellulose, starch, pregelatinized starch, modified starch, dibasic calcium phosphate dihydrate, calcium sulfate trihydrate, calcium sulfate dihydrate, calcium carbonate, dextrose, sucrose, lactose, mannitol, and sorbitol. 
Povoljan plastifikator za uporabu sa polimerom enteričke obloge je kombinacija trietil citrata 1 glicerol monostearata, Povoljna punila uključuju, ali nisu ograničena na, mikrokristaliničnu celulozu, škrob, preželatinizirani škrob, modificirani škrob, dibazičan kalcij fosfat dihidrat, kalcij sulfat trihidrat, kalcij sulfat dihidrat, kalcij karbonat, dekstrozu, saharozu, laktozu, manitol i sorbitol.
The liquefied gas treatment system according to claim 3, wherein the sub LNG supply line includes a gas-liquid separator configured to separate a heavy hydrocarbon component from the LNG so as to adjust a methane number of the fuel to a value necessary for the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje separator plina od tekućine (23), konfiguriran za razdvajanje BOG-a, koji se dekomprimira u plinovito-tekuće miješano stanje prilikom prolaska kroz element za dekomprimiranje (22), na plinovitu komponentu i tekuću komponentu.
The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. 
Gornje formulacije mogu se pripraviti konvencionalnim postupcima poznatim u farmaceutskoj struci.
RA is 5 to 6-membered heteroaryl optionally substituted by 1, 2, or 3 substituents independently selected from RCy; or 
RA je 5 to 6-člani heteroaril izborno supstituiran sa 1, 2, ili 3 supstituenta nezavisno izabrana od RCy; ili
The lamellas of each group of lamellas preferably overlap. 
Poželjno je da se lamele od svake skupine lamela preklapaju.
providing a container comprising a base and a continuous side wall upstanding from the base with a peripheral flange formed along the upper, in use, edge of the continuous side wall, wherein the base and continuous side wall consists essentially of PET; and 
pružanje posude koja sadrži osnovu i kontinuirani bočni zid koji se proteže čvrsto okomito na osnovu sa obodom formiranim duž gornjeg, pri upotrebi, ivice kontinuiranog bočnog zida, pri čemu se osnova i kontinuirani bočni zid u osnovi sastoje od polietilen tereftalata (PET); i
The compound according to claim 12, wherein the compound of Formula Bf is selected from: and or a pharmaceutically acceptable form thereof. 
Spoj iz zahtjeva 1, pri čemu je spoj: ili njegova farmaceutski prihvatljiva sol.
A composition, comprising an antisense oligonucleotide of claim 1 or claim 2 and a pharmaceutically acceptable carrier. An antisense oligonucleotide of claim 1 or 2, or a composition of claim 3, for use in treatment of muscular dystrophy. 
Antisens oligonukleotid u skladu s bilo kojim od patentnih zahtjeva 1 do 17 ili pripravak u skladu s patentnim zahtjevom 18, naznačen time što je namijenjen upotrebi u postupku liječenja mišićne distrofije kod pacijenta.
converting a medium containing a pentose source with a cell according to any of claims 9 to 12, which converts pentose to a bioalcohol, optionally obtaining the bioalcohol, wherein the pentose is preferably arabinose, more preferably L-arabinose, and wherein the bioalcohol is bioethanol and/or biobutanol. 
(a)prevođenja medija koji sadrži izvor L-arabinoze stanicom u skladu s bilo kojim od patentnih zahtjeva 9 do 11, koja prevodi L-arabinozu u bioalkohol, (b) izbornog dobivanja bioalkohola, gdje je bioalkohol bioetanol i/ili biobutanol.
at least a subset of said locking tumblers comprising a body part (206 a) and an integral key sensing part (206 b) for engagement with a longitudinal code pattern of an associated key (100), said body part being mounted in an associated chamber (208) in said key plug for elevational movement therein along a tumbler axis in parallel to the axis of said associated chamber, wherein 
- - barem podskup navedenih čepića za zaključavanje sadrži dio kućišta (2064) 1 integralni dio za raspoznavanje ključa (206b) koji surađuje sa uzdužnim kodnim uzorkom pripadajućeg ključa (100), a navedeni dio kućišta je postavljen u odgovarajuću komoru (208) u navedenom ulošku za ključ radi vertikalnog pomicanja uzduž osi čepića paralelno s osi navedene odgovarajuće komore,
Selenite may e.g. be comprised in the medium as sodium selenite. 
Selenit u mediju može biti kao pr. natrijev selenit.
cultivating a microorganism according to claim 4, in a culture medium comprising at least one carbon source and one nitrogen source, under conditions allowing the production of isopropanol, and 
- <0kultiviranje mikroorganizma u skladu s bilo kojim od patentnih zahtjeva 4 do 8, u mediju kulture koji sadržava najmanje jedan izvor ugljika 1 jedan izvor dušika pod uvjetima koji omogućuju proizvodnju izopropanola,
An anti-IL-1B antibody or IL-1B-binding fragment thereof for use of claim 13, wherein said at least one pharmaceutical composition comprising an active agent other than an IL-1B antibody or fragment is selected from the group consisting of a nonsteroidal anti-inflammatory drug (NSAID), a corticosteroid, an adrenocorticotropic hormone, and a colchicines. 
Anti-IL-1B protutijelo ili njegov IL-1B-vezujući fragment za uporabu prema zahtjevu 13, gdje se taj barem jedan farmaceutski oblik koji sadrži djelatnu tvar koja nije IL-1B protutijelo ili fragment izabire iz skupine koja obuhvaća nesteroidni protuupalni lijek (NSAID), kortikosteroid, adrenokortikotropni hormon i kolhicin.
A compound of claim 1 of formula IIC: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav prema patentnom zahtjevu 1 pri čemu spoj formule IIB je spoj formule IIC: ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili ester, pri čemu:
The method of claim 1, wherein the active indicator substance comprises at least one IR indicator substance selected from the group consisting of doped strontium sulfide, doped zinc sulfide, yttrium compounds, ytterbium compounds and erbium compounds. The method of claim 1, wherein the active indicator substance is water soluble. 
Mineralna vuna kao proizvod u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što mineralna vuna kao proizvod sadrži najmanje jednu IR-aktivnu komponentu, koju se bira iz skupine koju čine dopirani stroncijev sulfid, dopirani cinkov sulfid, itrijevi spojevi, iterbijevi spojevi i erbijevi spojevi.
wherein the ACE inhibitor is selected from the group consisting of omapatrilat, MDL100240, alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat and spirapril or a pharmaceutically acceptable derivative thereof; and/or 
Pimobendan prema bilo kojem od prethodnih zahtjeva, naznačen time, da je ACE inhibitor odabran iz skupine koju čine omapatrilat, MDL100240, alacepril, benazepril, kaptopril, silazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lizinopril, perindopril, kvinapnil, ramipril, ramiprilat, saralazin acetat, temokapril, trandolapril, trandolaprilat, ceranapril, moeksipril, kvinaprilat i spirapril.
The pharmaceutical composition according to claims 8 or 9, which further comprises an anticoagulant agent, preferably heparin, dicoumarol, acenocoumarol, enoxaparine or pentosan polysulfate. 
Farmaceutski sastav prema zahtjevu 8 ili 9, naznačen time, da on nadalje sadrži antikoagulantno sredstvo, ponajprije heparin, dikumarol, acenokumarol, enoksaparin ili pentosan polisulfat.
Highest clones Number of 
Broj međunarodne objave:
The use of the system according to claim 1, wherein the two compositions of the two components of the system are in separate compartments. 
Upotreba sustava u skladu sa zahtjevom 1, naznačena time, što su dva sastava od dviju komponenta sustava u zasebnim odjeljcima.
In another embodiment of the invention, the dermal micro-organ includes part of the cross-section of the dermis. 
Uporaba iz patentnog zahtjeva 8, naznačena time, da navedeni dermalni mikroorgan sadrži najmanje dio poprečnog presjeka dermisa.
The compound for use according to claim 1, wherein R2 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; optionally wherein R2 is heterocycloalkyl selected from the group consisting of substituted or unsubstituted oxanyl, substituted or unsubstituted oxetanyl, and substituted or unsubstituted morpholinyl. 
Spoj za uporabu prema zahtjevu 1, naznačen time što je R2 supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani cikloalkil, ili supstituirani ili nesupstituirani heterocikloalkil; proizvoljno pri je čemu R2 heterocikloalkil odabran iz skupine koju čine supstituirani ili nesupstituirani oksanil, supstituirani ili nesupstituirani oksetanil, i supstituirani ili nesupstituirani morfolinil.
The method of claim 16, wherein the pharmaceutical topical composition is selected from the group consisting of solutions, creams, lotions, unguents, emulsions, and suspensions. 
Farmaceutski topikalni pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što se bira iz skupine koju čine otopine, kreme, losioni, masti, emulzije, te suspenzije.
The device according to claim 11 wherein the pair of DVRBs assigned with the single resource block number are mapped to PRBs that are different in a time domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 13, naznačen time da su DVRB-i s ne-uzastopnim DVRB brojevima mapirani na dva od PRB-a koji su susjedni u frekvencijskoj domeni.
The compound for use according to embodiment 11, wherein the disease is psoriatic arthritis. 
Spoj za upotrebu prema zahtjevu 18, pri čemu je bolest psorijazni artritis.
coupling of the compound of general structure IIIa from step c) or d) with an amine of general structure IIa, 
6) spajanje spoja općenite strukture IIIa iz koraka c) ili d) s aminom općenite strukture IIa,
Helmet (3) in particular work or sports protective helmet, comprising a structure having at least one substantially convex outer surface and at least one substantially concave inner surface (3a) adapted to receive in engagement a user's head; characterised in that it comprises at least one forehead support band (1) according to one or more of the preceding claims. 
Kaciga (3), osobito radna ili sportska zaštitna kaciga, koja ima strukturu s najmanje jednom uglavnom izbočenom vanjskom površinom i najmanje jednom uglavnom udubljenom unutarnjom površinom (3a), prilagođena za prihvaćanje korisnikove glave u međudjelovanju; naznačena time što ima najmanje jednu vrpcu za podržavanje čela (1) u skladu s jednim ili više od prethodnih patentnih zahtjeva.
The cholesterol-reduced ruminant dairy product for use in the treatment and/or the prevention of a liver disease according to claim 5 wherein the spread is butter or a spreadable butter. 
Prehrambeni mliječni proizvod sa smanjenim kolesterolom za uporabu u liječenju iili sprječavanju bolesti jetre prema zahtjevu 5 naznačen time da namaz je maslac ili maslac koji se može razmazati.
Moreover, the device does not allow for visualisation during the medical procedure. 
Osim toga, ovaj uređaj nc omogućava promatranje za vrijeme medicinskog postupka.
15 wherein n is 1, 2 or 3, and BAA is a basic amino acid. As basic amino acids basic arginine, lysine, ornithine or others, in L-, D- or DL-form, preferably L-arginine, are used. 
CD) gdje BAA znači bazična aminokiselina. 2. | Nove stabilne soli pentadekapeptida formule (1), naznačene time, da bazične aminokiseline su arginin, lizin, ornitin ili neke druge, u L-obliku, D-obliku ili DL-obliku, a posebno je to L-arginin.
The method according to claim 1, wherein the disease or disorder is liver cancer, wherein the liver cancer is hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, or hemagioma. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak gušterače.
A drug delivery device suitable for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least one day after administration wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge having 3.6 to 8mg/cm3 type I collagen, and 2.0 to 6.0mg/cm3 bupivacaine hydrochloride. 
Naprava za dopremu lijeka pogodna za omogućavanje lokalne analgezije, lokalne anestezije ili blokade živca na određenom mjestu kod potrebitog čovjeka ili životinje, naprava obuhvaća matricu od fibrilarnog kolagena; i barem jednu ljekovitu tvar, najmanje jedna ljekovita tvar je sadržajno homogeno raspršena u matrici kolagena, pri čemu naprava za dopremu lijeka sadrži jednu ili nekoliko liofiliziranih kolagen spužvi koje ukupno sadrže 250 mg ili 200 mg anhidridnog bupivakain hidroklorida.
Advantageously, the method according to the invention is characterized in that the incision step is performed before said unwinding of the shrink film. 
Postupak u skladu sa zahtjevom 8, naznačen time što se navedeni korak reza izvodi prije navedenog odmotavanja stezne folije.
The kit as claimed in claim 11, wherein the lysis buffer is as defined in claim 3, the binding buffer is as defined in claim 4, the washing buffer is as defined in claims 5 to 8, and/or the eluting buffer is as defined in claim 9. 
Komplet u skladu s patentnim zahtjevom 11, naznačen time što je pufer za lizu definiran kao u patentnim zahtjevom 3, pufer za vezanje je definiran kao u patentnim zahtjevom 4, pufer za ispiranje je definiran kao u patentnih zahtjeva 5 do 8, i/ili pufer za eluiranje je definiran kao u patentnim zahtjevom 9.